Aug 8 (Reuters) - Merck ( MRK ) said on Thursday it had
discontinued its trial of a combination of its experimental drug
and blockbuster therapy Keytruda for the treatment of a type of
lung cancer, after an interim analysis showed the drug was
unlikely to succeed.
(Reporting by Leroy Leo in Bengaluru; Editing by Devika
Syamnath)